IL303925A - Compounds comprising a fibroblast activation protein ligand and use thereof - Google Patents

Info

Publication number

IL303925A

IL303925A IL303925A IL30392523A IL303925A IL 303925 A IL303925 A IL 303925A IL 303925 A IL303925 A IL 303925A IL 30392523 A IL30392523 A IL 30392523A IL 303925 A IL303925 A IL 303925A

Authority

IL

Israel

Prior art keywords

group

compound

amino acid

cys

pro

Prior art date

2021-01-07

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 639
• 210000002950 fibroblast Anatomy 0.000 title claims description 63
• 108090000623 proteins and genes Proteins 0.000 title claims description 41
• 102000004169 proteins and genes Human genes 0.000 title claims description 40
• 230000004913 activation Effects 0.000 title claims description 36
• 239000003446 ligand Substances 0.000 title description 6
• -1 CHX-A"-DTPA Chemical compound 0.000 claims description 237
• 150000001413 amino acids Chemical class 0.000 claims description 225
• 125000000539 amino acid group Chemical group 0.000 claims description 215
• 201000010099 disease Diseases 0.000 claims description 161
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 161
• 239000002738 chelating agent Substances 0.000 claims description 137
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 120
• 238000000034 method Methods 0.000 claims description 87
• 125000000217 alkyl group Chemical group 0.000 claims description 72
• 125000003118 aryl group Chemical group 0.000 claims description 69
• 125000001424 substituent group Chemical group 0.000 claims description 68
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 57
• 238000011282 treatment Methods 0.000 claims description 44
• 125000004434 sulfur atom Chemical group 0.000 claims description 42
• 229910052757 nitrogen Inorganic materials 0.000 claims description 40
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 38
• 238000003745 diagnosis Methods 0.000 claims description 37
• 238000011191 terminal modification Methods 0.000 claims description 36
• 150000003568 thioethers Chemical class 0.000 claims description 35
• FRJNIHLOMXIQKH-UHFFFAOYSA-N 1-amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid Chemical group NCCCOCCOCCOCCCNC(=O)CCC(O)=O FRJNIHLOMXIQKH-UHFFFAOYSA-N 0.000 claims description 34
• 229910052736 halogen Inorganic materials 0.000 claims description 34
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 32
• 229910052717 sulfur Inorganic materials 0.000 claims description 31
• 108010069514 Cyclic Peptides Proteins 0.000 claims description 29
• 102000001189 Cyclic Peptides Human genes 0.000 claims description 29
• 150000002367 halogens Chemical class 0.000 claims description 28
• 239000003112 inhibitor Substances 0.000 claims description 27
• 125000005365 aminothiol group Chemical group 0.000 claims description 26
• 229910052731 fluorine Inorganic materials 0.000 claims description 26
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 26
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 25
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 25
• 229910052739 hydrogen Inorganic materials 0.000 claims description 25
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 24
• 125000001072 heteroaryl group Chemical group 0.000 claims description 24
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 23
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 22
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 22
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 21
• JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 20
• 229910052760 oxygen Inorganic materials 0.000 claims description 20
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
• JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 19
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
• 230000000903 blocking effect Effects 0.000 claims description 18
• 230000015572 biosynthetic process Effects 0.000 claims description 17
• 210000004899 c-terminal region Anatomy 0.000 claims description 17
• SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 claims description 15
• 229910052794 bromium Inorganic materials 0.000 claims description 15
• 229910052801 chlorine Inorganic materials 0.000 claims description 15
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
• 238000006467 substitution reaction Methods 0.000 claims description 15
• FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims description 14
• 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 13
• FQIHLPGWBOBPSG-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC1 FQIHLPGWBOBPSG-UHFFFAOYSA-N 0.000 claims description 13
• NVOVSXGZALWAFS-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane Chemical compound C1NCCNCC2CNCCNCC1CNCCNC2 NVOVSXGZALWAFS-UHFFFAOYSA-N 0.000 claims description 13
• 125000004122 cyclic group Chemical group 0.000 claims description 13
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
• 229910003204 NH2 Inorganic materials 0.000 claims description 12
• 101100326677 Onchocerca volvulus crt-1 gene Proteins 0.000 claims description 12
• 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 claims description 12
• 108010070783 alanyltyrosine Proteins 0.000 claims description 12
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 12
• RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 claims description 12
• GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 claims description 11
• 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 10
• 125000000623 heterocyclic group Chemical group 0.000 claims description 10
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
• 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 8
• 150000008575 L-amino acids Chemical group 0.000 claims description 7
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 6
• 150000008574 D-amino acids Chemical class 0.000 claims description 5
• ACHQFNGCBWWVRR-UHFFFAOYSA-N NOPO Chemical compound NOPO ACHQFNGCBWWVRR-UHFFFAOYSA-N 0.000 claims 4
• 241001181114 Neta Species 0.000 claims 4
• GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 claims 4
• 230000005264 electron capture Effects 0.000 description 228
• 206010028980 Neoplasm Diseases 0.000 description 199
• 235000001014 amino acid Nutrition 0.000 description 183
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 132
• 210000004027 cell Anatomy 0.000 description 123
• 125000005647 linker group Chemical group 0.000 description 100
• 201000011510 cancer Diseases 0.000 description 75
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 56
• 230000003211 malignant effect Effects 0.000 description 49
• 210000001519 tissue Anatomy 0.000 description 46
• 235000018102 proteins Nutrition 0.000 description 37
• 206010025323 Lymphomas Diseases 0.000 description 29
• 201000009030 Carcinoma Diseases 0.000 description 25
• 230000001225 therapeutic effect Effects 0.000 description 25
• 201000001441 melanoma Diseases 0.000 description 24
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 23
• 239000000203 mixture Substances 0.000 description 23
• 230000004083 survival effect Effects 0.000 description 22
• 208000035269 cancer or benign tumor Diseases 0.000 description 21
• 230000003902 lesion Effects 0.000 description 20
• 208000009956 adenocarcinoma Diseases 0.000 description 19
• 201000011519 neuroendocrine tumor Diseases 0.000 description 18
• 241000282414 Homo sapiens Species 0.000 description 17
• 206010039491 Sarcoma Diseases 0.000 description 16
• 229940125666 actinium-225 Drugs 0.000 description 16
• 125000004429 atom Chemical group 0.000 description 16
• 208000003200 Adenoma Diseases 0.000 description 15
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 102000004196 processed proteins & peptides Human genes 0.000 description 15
• 206010027406 Mesothelioma Diseases 0.000 description 14
• UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 14
• 239000002253 acid Substances 0.000 description 14
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 14
• 229910052751 metal Chemical group 0.000 description 14
• 239000002184 metal Chemical group 0.000 description 14
• 208000026310 Breast neoplasm Diseases 0.000 description 13
• 208000024172 Cardiovascular disease Diseases 0.000 description 13
• 206010009944 Colon cancer Diseases 0.000 description 13
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 13
• 206010027145 Melanocytic naevus Diseases 0.000 description 13
• 125000003275 alpha amino acid group Chemical group 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 230000003176 fibrotic effect Effects 0.000 description 13
• 230000002285 radioactive effect Effects 0.000 description 13
• 150000003839 salts Chemical class 0.000 description 13
• 206010041823 squamous cell carcinoma Diseases 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• 206010006187 Breast cancer Diseases 0.000 description 12
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 12
• 206010061535 Ovarian neoplasm Diseases 0.000 description 12
• 239000000460 chlorine Substances 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• ZNYVGVMHKCUCAT-UHFFFAOYSA-N 3-[[4,7-bis[[hydroxy(hydroxymethyl)phosphoryl]methyl]-1,4,7-triazonan-1-yl]methyl-hydroxyphosphoryl]propanoic acid Chemical compound OCP(O)(=O)CN1CCN(CP(O)(=O)CO)CCN(CP(O)(=O)CCC(O)=O)CC1 ZNYVGVMHKCUCAT-UHFFFAOYSA-N 0.000 description 11
• 206010001233 Adenoma benign Diseases 0.000 description 11
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
• 150000001408 amides Chemical class 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 208000006990 cholangiocarcinoma Diseases 0.000 description 11
• 239000012636 effector Substances 0.000 description 11
• 210000002889 endothelial cell Anatomy 0.000 description 11
• 201000005202 lung cancer Diseases 0.000 description 11
• 208000020816 lung neoplasm Diseases 0.000 description 11
• 230000036210 malignancy Effects 0.000 description 11
• 206010027191 meningioma Diseases 0.000 description 11
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
• VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 10
• 206010033128 Ovarian cancer Diseases 0.000 description 10
• 206010060862 Prostate cancer Diseases 0.000 description 10
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
• 208000006265 Renal cell carcinoma Diseases 0.000 description 10
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
• 206010003246 arthritis Diseases 0.000 description 10
• 125000004432 carbon atom Chemical group C* 0.000 description 10
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 10
• 201000010536 head and neck cancer Diseases 0.000 description 10
• 208000014829 head and neck neoplasm Diseases 0.000 description 10
• 208000027866 inflammatory disease Diseases 0.000 description 10
• 230000000527 lymphocytic effect Effects 0.000 description 10
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 10
• 230000007170 pathology Effects 0.000 description 10
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
• 125000001118 alkylidene group Chemical group 0.000 description 9
• 210000000481 breast Anatomy 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 9
• XMSHRLOQLUNKSN-UHFFFAOYSA-N destosyl pyrazolate Chemical compound CC1=NN(C)C(O)=C1C(=O)C1=CC=C(Cl)C=C1Cl XMSHRLOQLUNKSN-UHFFFAOYSA-N 0.000 description 9
• 150000002148 esters Chemical class 0.000 description 9
• 230000003325 follicular Effects 0.000 description 9
• 206010017758 gastric cancer Diseases 0.000 description 9
• 238000003384 imaging method Methods 0.000 description 9
• 208000032839 leukemia Diseases 0.000 description 9
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 9
• 206010061289 metastatic neoplasm Diseases 0.000 description 9
• 201000002528 pancreatic cancer Diseases 0.000 description 9
• 208000008443 pancreatic carcinoma Diseases 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 210000002536 stromal cell Anatomy 0.000 description 9
• SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 8
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 8
• 206010004146 Basal cell carcinoma Diseases 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 8
• 108700020796 Oncogene Proteins 0.000 description 8
• 208000005718 Stomach Neoplasms Diseases 0.000 description 8
• 230000000536 complexating effect Effects 0.000 description 8
• 150000004696 coordination complex Chemical class 0.000 description 8
• 239000000032 diagnostic agent Substances 0.000 description 8
• 229940039227 diagnostic agent Drugs 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 230000001394 metastastic effect Effects 0.000 description 8
• 201000008968 osteosarcoma Diseases 0.000 description 8
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
• 201000011549 stomach cancer Diseases 0.000 description 8
• 206010003571 Astrocytoma Diseases 0.000 description 7
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
• 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 7
• 208000024770 Thyroid neoplasm Diseases 0.000 description 7
• 239000013543 active substance Substances 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 208000002458 carcinoid tumor Diseases 0.000 description 7
• 238000002591 computed tomography Methods 0.000 description 7
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 7
• 230000001965 increasing effect Effects 0.000 description 7
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
• 210000000496 pancreas Anatomy 0.000 description 7
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
• 230000008685 targeting Effects 0.000 description 7
• 201000002510 thyroid cancer Diseases 0.000 description 7
• 208000009888 Adrenocortical Adenoma Diseases 0.000 description 6
• 201000001320 Atherosclerosis Diseases 0.000 description 6
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 6
• 206010005003 Bladder cancer Diseases 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• 206010007275 Carcinoid tumour Diseases 0.000 description 6
• 206010008342 Cervix carcinoma Diseases 0.000 description 6
• 208000011231 Crohn disease Diseases 0.000 description 6
• 206010014733 Endometrial cancer Diseases 0.000 description 6
• 206010014759 Endometrial neoplasm Diseases 0.000 description 6
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 6
• 201000008808 Fibrosarcoma Diseases 0.000 description 6
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 6
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
• 208000015234 adrenal cortex adenoma Diseases 0.000 description 6
• 201000003354 adrenal cortical adenoma Diseases 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 6
• 201000010881 cervical cancer Diseases 0.000 description 6
• 208000019425 cirrhosis of liver Diseases 0.000 description 6
• 201000004101 esophageal cancer Diseases 0.000 description 6
• 210000002744 extracellular matrix Anatomy 0.000 description 6
• 206010016629 fibroma Diseases 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• UKAUYVFTDYCKQA-UHFFFAOYSA-N homoserine Chemical group OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 6
• 238000002372 labelling Methods 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 239000008177 pharmaceutical agent Substances 0.000 description 6
• 230000005258 radioactive decay Effects 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 210000002784 stomach Anatomy 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 5
• 206010018338 Glioma Diseases 0.000 description 5
• 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 5
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
• 101710178372 Prolyl endopeptidase Proteins 0.000 description 5
• 206010042658 Sweat gland tumour Diseases 0.000 description 5
• 206010043276 Teratoma Diseases 0.000 description 5
• 208000007536 Thrombosis Diseases 0.000 description 5
• 239000007983 Tris buffer Substances 0.000 description 5
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000002585 base Chemical class 0.000 description 5
• 125000003636 chemical group Chemical group 0.000 description 5
• 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 5
• 210000003238 esophagus Anatomy 0.000 description 5
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 5
• 201000007270 liver cancer Diseases 0.000 description 5
• 208000014018 liver neoplasm Diseases 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 5
• 210000000214 mouth Anatomy 0.000 description 5
• 208000004707 mucinous cystadenoma Diseases 0.000 description 5
• 208000025113 myeloid leukemia Diseases 0.000 description 5
• 208000010125 myocardial infarction Diseases 0.000 description 5
• 238000013517 stratification Methods 0.000 description 5
• NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 5
• 125000003396 thiol group Chemical group [H]S* 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• 201000005112 urinary bladder cancer Diseases 0.000 description 5
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 4
• 208000005440 Basal Cell Neoplasms Diseases 0.000 description 4
• 201000000274 Carcinosarcoma Diseases 0.000 description 4
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 206010014967 Ependymoma Diseases 0.000 description 4
• 206010073064 Epithelioid mesothelioma Diseases 0.000 description 4
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 4
• 206010019043 Hair follicle tumour benign Diseases 0.000 description 4
• 206010024305 Leukaemia monocytic Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 208000007871 Odontogenic Tumors Diseases 0.000 description 4
• 208000010191 Osteitis Deformans Diseases 0.000 description 4
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
• 208000009077 Pigmented Nevus Diseases 0.000 description 4
• 208000007452 Plasmacytoma Diseases 0.000 description 4
• 208000002664 Pleural Solitary Fibrous Tumor Diseases 0.000 description 4
• 239000004721 Polyphenylene oxide Substances 0.000 description 4
• 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
• 241000011102 Thera Species 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 201000004471 adenofibroma Diseases 0.000 description 4
• 230000003143 atherosclerotic effect Effects 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 239000004202 carbamide Substances 0.000 description 4
• 125000002843 carboxylic acid group Chemical group 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• 239000003814 drug Substances 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• 229910052733 gallium Inorganic materials 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 230000009545 invasion Effects 0.000 description 4
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
• 208000003747 lymphoid leukemia Diseases 0.000 description 4
• 208000025036 lymphosarcoma Diseases 0.000 description 4
• 208000014699 malignant epithelioid mesothelioma Diseases 0.000 description 4
• 201000010078 malignant spindle cell melanoma Diseases 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 210000004877 mucosa Anatomy 0.000 description 4
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 208000004128 odontoma Diseases 0.000 description 4
• 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 208000003154 papilloma Diseases 0.000 description 4
• 208000007312 paraganglioma Diseases 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 229910052698 phosphorus Inorganic materials 0.000 description 4
• 229920000570 polyether Polymers 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 4
• 201000002025 prostate sarcoma Diseases 0.000 description 4
• 201000001513 prostate squamous cell carcinoma Diseases 0.000 description 4
• 239000012217 radiopharmaceutical Substances 0.000 description 4
• 229940121896 radiopharmaceutical Drugs 0.000 description 4
• 230000002799 radiopharmaceutical effect Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 238000007363 ring formation reaction Methods 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 208000005893 serous cystadenoma Diseases 0.000 description 4
• 208000019798 spindle cell melanoma Diseases 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 206010044412 transitional cell carcinoma Diseases 0.000 description 4
• 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 4
• ULBLZIPFWGIOJF-QMMMGPOBSA-N (2s)-2-(bromoamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](NBr)CC1=CC=CC=C1 ULBLZIPFWGIOJF-QMMMGPOBSA-N 0.000 description 3
• XCKUCSJNPYTMAE-QMMMGPOBSA-N (2s)-2-(chloroamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](NCl)CC1=CC=CC=C1 XCKUCSJNPYTMAE-QMMMGPOBSA-N 0.000 description 3
• IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 3
• OPOTYPXOKUZEKY-QMMMGPOBSA-N (2s)-2-nitramido-3-phenylpropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=CC=C1 OPOTYPXOKUZEKY-QMMMGPOBSA-N 0.000 description 3
• OOHQXLBZBXABCV-QMMMGPOBSA-N (2s)-3-phenyl-2-(trifluoromethylamino)propanoic acid Chemical compound FC(F)(F)N[C@H](C(=O)O)CC1=CC=CC=C1 OOHQXLBZBXABCV-QMMMGPOBSA-N 0.000 description 3
• UDOPJKHABYSVIX-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN(CC(O)=O)C1CC1=CC=C(N=C=S)C=C1 UDOPJKHABYSVIX-UHFFFAOYSA-N 0.000 description 3
• GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 description 3
• RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 description 3
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 208000004804 Adenomatous Polyps Diseases 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 208000003609 Bile Duct Adenoma Diseases 0.000 description 3
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical class OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
• 208000007690 Brenner tumor Diseases 0.000 description 3
• 206010073258 Brenner tumour Diseases 0.000 description 3
• VHRGRCVQAFMJIZ-UHFFFAOYSA-N Cadaverine Natural products NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
• 208000005243 Chondrosarcoma Diseases 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 229910052692 Dysprosium Inorganic materials 0.000 description 3
• 102000005593 Endopeptidases Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 229910052693 Europium Inorganic materials 0.000 description 3
• 208000006168 Ewing Sarcoma Diseases 0.000 description 3
• 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 208000006050 Hemangiopericytoma Diseases 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 3
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
• 102000004157 Hydrolases Human genes 0.000 description 3
• 108090000604 Hydrolases Proteins 0.000 description 3
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 3
• 208000018142 Leiomyosarcoma Diseases 0.000 description 3
• 229910052765 Lutetium Inorganic materials 0.000 description 3
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 208000007054 Medullary Carcinoma Diseases 0.000 description 3
• 208000000172 Medulloblastoma Diseases 0.000 description 3
• 208000010153 Mesonephroma Diseases 0.000 description 3
• 206010054949 Metaplasia Diseases 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 206010027459 Metastases to lymph nodes Diseases 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 201000004404 Neurofibroma Diseases 0.000 description 3
• 208000007256 Nevus Diseases 0.000 description 3
• 201000010133 Oligodendroglioma Diseases 0.000 description 3
• 208000027868 Paget disease Diseases 0.000 description 3
• 208000002163 Phyllodes Tumor Diseases 0.000 description 3
• 208000007641 Pinealoma Diseases 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 201000000582 Retinoblastoma Diseases 0.000 description 3
• 208000005678 Rhabdomyoma Diseases 0.000 description 3
• 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 3
• 208000008383 Wilms tumor Diseases 0.000 description 3
• 206010052428 Wound Diseases 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000002707 ameloblastic effect Effects 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
• 208000007047 blue nevus Diseases 0.000 description 3
• 238000004364 calculation method Methods 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 239000010949 copper Substances 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
• 238000000097 high energy electron diffraction Methods 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 206010022498 insulinoma Diseases 0.000 description 3
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
• 150000002540 isothiocyanates Chemical class 0.000 description 3
• 210000001503 joint Anatomy 0.000 description 3
• 208000022013 kidney Wilms tumor Diseases 0.000 description 3
• 206010024627 liposarcoma Diseases 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 3
• 208000027202 mammary Paget disease Diseases 0.000 description 3
• 208000004197 mesenchymoma Diseases 0.000 description 3
• 208000011831 mesonephric neoplasm Diseases 0.000 description 3
• 230000015689 metaplastic ossification Effects 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 201000006894 monocytic leukemia Diseases 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 3
• SCIFESDRCALIIM-UHFFFAOYSA-N n-methylphenylalanine Chemical compound CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 3
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• 230000009826 neoplastic cell growth Effects 0.000 description 3
• 201000008026 nephroblastoma Diseases 0.000 description 3
• 208000027831 neuroepithelial neoplasm Diseases 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 208000027825 odontogenic neoplasm Diseases 0.000 description 3
• 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• 208000021255 pancreatic insulinoma Diseases 0.000 description 3
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
• 229960003330 pentetic acid Drugs 0.000 description 3
• 239000011574 phosphorus Chemical group 0.000 description 3
• 208000037244 polycythemia vera Diseases 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 201000006845 reticulosarcoma Diseases 0.000 description 3
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 3
• 229910052702 rhenium Inorganic materials 0.000 description 3
• 208000014212 sarcomatoid carcinoma Diseases 0.000 description 3
• 229950008684 sibrotuzumab Drugs 0.000 description 3
• 238000002603 single-photon emission computed tomography Methods 0.000 description 3
• 208000000649 small cell carcinoma Diseases 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 229940124530 sulfonamide Drugs 0.000 description 3
• 150000003456 sulfonamides Chemical class 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 206010042863 synovial sarcoma Diseases 0.000 description 3
• 229910052713 technetium Inorganic materials 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 3
• 208000010556 transitional cell papilloma Diseases 0.000 description 3
• 201000004420 transitional papilloma Diseases 0.000 description 3
• 150000003852 triazoles Chemical class 0.000 description 3
• 230000004614 tumor growth Effects 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 229910052727 yttrium Inorganic materials 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 2
• KIUIVKNVSSLOAG-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotridecan-11-one Chemical compound O=C1CCNCCNCCNCCN1 KIUIVKNVSSLOAG-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• AJPADPZSRRUGHI-RFZPGFLSSA-N 1-deoxy-D-xylulose 5-phosphate Chemical compound CC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O AJPADPZSRRUGHI-RFZPGFLSSA-N 0.000 description 2
• VVJIVFKAROPUOS-UHFFFAOYSA-N 2,2-bis(aminomethyl)propane-1,3-diamine Chemical compound NCC(CN)(CN)CN VVJIVFKAROPUOS-UHFFFAOYSA-N 0.000 description 2
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
• RPNMGUBLKCLAEK-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n,n-diethylethanamine;hydrochloride Chemical compound [Cl-].CC[NH+](CC)CCSC1=CC=C(Cl)C=C1 RPNMGUBLKCLAEK-UHFFFAOYSA-N 0.000 description 2
• HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 2
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 2
• 125000005916 2-methylpentyl group Chemical group 0.000 description 2
• UQQQAKFVWNQYTP-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane-1,8-diamine Chemical compound C1NCCNCC2(N)CNCCNCC1(N)CNCCNC2 UQQQAKFVWNQYTP-UHFFFAOYSA-N 0.000 description 2
• 125000005917 3-methylpentyl group Chemical group 0.000 description 2
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
• KJSJBKBZMGSIPT-UHFFFAOYSA-N 4-oxo-3-phenylmethoxypyran-2-carboxylic acid Chemical compound O1C=CC(=O)C(OCC=2C=CC=CC=2)=C1C(=O)O KJSJBKBZMGSIPT-UHFFFAOYSA-N 0.000 description 2
• 208000007876 Acrospiroma Diseases 0.000 description 2
• 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 101710130081 Aspergillopepsin-1 Proteins 0.000 description 2
• 206010065869 Astrocytoma, low grade Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
• XTHKVNZIGSIYAV-UHFFFAOYSA-N C(=O)(O)CCC(N1CCN(CCN(CC1)C([PH2]=O)(O)CCC(=O)O)CP(=O)(CCC(=O)O)O)([PH2]=O)O Chemical compound C(=O)(O)CCC(N1CCN(CCN(CC1)C([PH2]=O)(O)CCC(=O)O)CP(=O)(CCC(=O)O)O)([PH2]=O)O XTHKVNZIGSIYAV-UHFFFAOYSA-N 0.000 description 2
• 101100074846 Caenorhabditis elegans lin-2 gene Proteins 0.000 description 2
• 101100181929 Caenorhabditis elegans lin-3 gene Proteins 0.000 description 2
• 101100243399 Caenorhabditis elegans pept-2 gene Proteins 0.000 description 2
• 206010007269 Carcinogenicity Diseases 0.000 description 2
• 208000007389 Cementoma Diseases 0.000 description 2
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
• 208000010126 Chondromatosis Diseases 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 208000004378 Choroid plexus papilloma Diseases 0.000 description 2
• 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
• 102000012422 Collagen Type I Human genes 0.000 description 2
• 108010022452 Collagen Type I Proteins 0.000 description 2
• 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 description 2
• 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 2
• 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 2
• 101100294331 Drosophila melanogaster nod gene Proteins 0.000 description 2
• 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 2
• 208000006402 Ductal Carcinoma Diseases 0.000 description 2
• 108010059378 Endopeptidases Proteins 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 229910052691 Erbium Inorganic materials 0.000 description 2
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
• 208000005163 Extra-Adrenal Paraganglioma Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 229910052687 Fermium Inorganic materials 0.000 description 2
• TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 229910052688 Gadolinium Inorganic materials 0.000 description 2
• 208000008999 Giant Cell Carcinoma Diseases 0.000 description 2
• 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 2
• 208000007569 Giant Cell Tumors Diseases 0.000 description 2
• 201000005618 Glomus Tumor Diseases 0.000 description 2
• 206010018404 Glucagonoma Diseases 0.000 description 2
• 208000005234 Granulosa Cell Tumor Diseases 0.000 description 2
• 208000002125 Hemangioendothelioma Diseases 0.000 description 2
• 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 229910052689 Holmium Inorganic materials 0.000 description 2
• 208000029966 Hutchinson Melanotic Freckle Diseases 0.000 description 2
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 description 2
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• 201000004462 Leydig Cell Tumor Diseases 0.000 description 2
• 206010024612 Lipoma Diseases 0.000 description 2
• 208000002404 Liver Cell Adenoma Diseases 0.000 description 2
• 206010025219 Lymphangioma Diseases 0.000 description 2
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
• 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 2
• 208000003351 Melanosis Diseases 0.000 description 2
• 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 2
• 208000000811 Mesothelial Neoplasms Diseases 0.000 description 2
• 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 101100497386 Mus musculus Cask gene Proteins 0.000 description 2
• 101000857304 Mus musculus Glomulin Proteins 0.000 description 2
• 206010073137 Myxoid liposarcoma Diseases 0.000 description 2
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
• SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
• 206010061309 Neoplasm progression Diseases 0.000 description 2
• 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 2
• 206010029488 Nodular melanoma Diseases 0.000 description 2
• 201000011436 Ossifying Fibroma Diseases 0.000 description 2
• 208000037064 Papilloma of choroid plexus Diseases 0.000 description 2
• 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 241000009328 Perro Species 0.000 description 2
• 206010071776 Phyllodes tumour Diseases 0.000 description 2
• 208000033014 Plasma cell tumor Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 229910052772 Samarium Inorganic materials 0.000 description 2
• 201000010208 Seminoma Diseases 0.000 description 2
• 208000003274 Sertoli cell tumor Diseases 0.000 description 2
• 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 206010068771 Soft tissue neoplasm Diseases 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 2
• 229910052771 Terbium Inorganic materials 0.000 description 2
• KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 229910052776 Thorium Inorganic materials 0.000 description 2
• 229910052775 Thulium Inorganic materials 0.000 description 2
• 229910052769 Ytterbium Inorganic materials 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 239000000370 acceptor Substances 0.000 description 2
• 229910052767 actinium Inorganic materials 0.000 description 2
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 2
• 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 125000003282 alkyl amino group Chemical group 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000005262 alpha decay Effects 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 2
• 208000006431 amelanotic melanoma Diseases 0.000 description 2
• 208000010029 ameloblastoma Diseases 0.000 description 2
• 208000009887 angiolipoma Diseases 0.000 description 2
• JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
• 229940049595 antibody-drug conjugate Drugs 0.000 description 2
• 229910052787 antimony Inorganic materials 0.000 description 2
• 229910052789 astatine Inorganic materials 0.000 description 2
• 208000016894 basaloid carcinoma Diseases 0.000 description 2
• 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 2
• 201000007551 basophilic adenocarcinoma Diseases 0.000 description 2
• 208000003373 basosquamous carcinoma Diseases 0.000 description 2
• 230000005255 beta decay Effects 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000002051 biphasic effect Effects 0.000 description 2
• 201000011143 bone giant cell tumor Diseases 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 201000003149 breast fibroadenoma Diseases 0.000 description 2
• 201000005201 breast intracanalicular fibroadenoma Diseases 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 230000007670 carcinogenicity Effects 0.000 description 2
• 231100000260 carcinogenicity Toxicity 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 210000003679 cervix uteri Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000013522 chelant Substances 0.000 description 2
• 229910052729 chemical element Inorganic materials 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 201000005217 chondroblastoma Diseases 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 201000010989 colorectal carcinoma Diseases 0.000 description 2
• 201000011050 comedo carcinoma Diseases 0.000 description 2
• 239000000562 conjugate Substances 0.000 description 2
• 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 229960003266 deferiprone Drugs 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 150000004985 diamines Chemical class 0.000 description 2
• 108700013553 diamsar chelate Proteins 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 2
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 2
• 201000003914 endometrial carcinoma Diseases 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 201000010877 epithelioid cell melanoma Diseases 0.000 description 2
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 2
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 230000005253 gamme decay Effects 0.000 description 2
• 201000008361 ganglioneuroma Diseases 0.000 description 2
• 201000011610 giant cell glioblastoma Diseases 0.000 description 2
• 208000002409 gliosarcoma Diseases 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 201000006604 granular cell tumor Diseases 0.000 description 2
• 201000011066 hemangioma Diseases 0.000 description 2
• 208000006359 hepatoblastoma Diseases 0.000 description 2
• 201000002735 hepatocellular adenoma Diseases 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 229910052738 indium Inorganic materials 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
• 230000007794 irritation Effects 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
• QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
• 230000000155 isotopic effect Effects 0.000 description 2
• 230000000366 juvenile effect Effects 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 244000144972 livestock Species 0.000 description 2
• 201000000014 lung giant cell carcinoma Diseases 0.000 description 2
• 201000006812 malignant histiocytosis Diseases 0.000 description 2
• 201000000289 malignant teratoma Diseases 0.000 description 2
• 229910052748 manganese Inorganic materials 0.000 description 2
• 239000011572 manganese Substances 0.000 description 2
• 201000006512 mast cell neoplasm Diseases 0.000 description 2
• 201000008203 medulloepithelioma Diseases 0.000 description 2
• 210000002752 melanocyte Anatomy 0.000 description 2
• 208000029796 mixed epithelioid and spindle cell melanoma Diseases 0.000 description 2
• 229910052750 molybdenum Inorganic materials 0.000 description 2
• 201000000720 morpheaform basal cell carcinoma Diseases 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 208000009091 myxoma Diseases 0.000 description 2
• 201000000032 nodular malignant melanoma Diseases 0.000 description 2
• 238000009377 nuclear transmutation Methods 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 229910052762 osmium Inorganic materials 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 208000003388 osteoid osteoma Diseases 0.000 description 2
• 208000008798 osteoma Diseases 0.000 description 2
• 210000003254 palate Anatomy 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 238000002638 palliative care Methods 0.000 description 2
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• 208000000793 papillary cystadenoma Diseases 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 208000028591 pheochromocytoma Diseases 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• 208000021857 pituitary gland basophilic carcinoma Diseases 0.000 description 2
• 208000031223 plasma cell leukemia Diseases 0.000 description 2
• 208000010626 plasma cell neoplasm Diseases 0.000 description 2
• 238000002600 positron emission tomography Methods 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
• 230000001950 radioprotection Effects 0.000 description 2
• 230000003439 radiotherapeutic effect Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 229910052703 rhodium Inorganic materials 0.000 description 2
• 239000010948 rhodium Substances 0.000 description 2
• 229910052707 ruthenium Inorganic materials 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 229910052706 scandium Inorganic materials 0.000 description 2
• 201000005253 serous surface papilloma Diseases 0.000 description 2
• 208000028467 sex cord-stromal tumor Diseases 0.000 description 2
• 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 2
• 229910052709 silver Inorganic materials 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 208000022159 squamous carcinoma in situ Diseases 0.000 description 2
• 201000005211 struma ovarii Diseases 0.000 description 2
• 125000000542 sulfonic acid group Chemical group 0.000 description 2
• 150000003460 sulfonic acids Chemical class 0.000 description 2
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
• 201000011138 superficial basal cell carcinoma Diseases 0.000 description 2
• 208000030034 superficial multifocal basal cell carcinoma Diseases 0.000 description 2
• 208000030457 superficial spreading melanoma Diseases 0.000 description 2
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 208000001644 thecoma Diseases 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 2
• 210000003384 transverse colon Anatomy 0.000 description 2
• 208000016811 trichoblastoma Diseases 0.000 description 2
• XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
• 230000005751 tumor progression Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• PSVXZQVXSXSQRO-UHFFFAOYSA-N undecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO PSVXZQVXSXSQRO-UHFFFAOYSA-N 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 208000009540 villous adenoma Diseases 0.000 description 2
• 229910052726 zirconium Inorganic materials 0.000 description 2
• VQJGUUHKSTYEGE-GCYSTPHZSA-N (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)C[C@@H](O)C1.N1[C@H](C(=O)O)C[C@@H](O)C1.N1[C@H](C(=O)O)C[C@@H](O)C1 VQJGUUHKSTYEGE-GCYSTPHZSA-N 0.000 description 1
• WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 description 1
• RHMALYOXPBRJBG-WXHCCQJTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s,3r)-2-[[(2s)-2-[[2-[[2-[[(2r)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]- Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RHMALYOXPBRJBG-WXHCCQJTSA-N 0.000 description 1
• UJJLJRQIPMGXEZ-BYPYZUCNSA-N (2s)-oxolane-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCO1 UJJLJRQIPMGXEZ-BYPYZUCNSA-N 0.000 description 1
• SHINASQYHDCLEU-IMJSIDKUSA-N (2s,4s)-4-aminopyrrolidine-2-carboxylic acid Chemical compound N[C@@H]1CN[C@H](C(O)=O)C1 SHINASQYHDCLEU-IMJSIDKUSA-N 0.000 description 1
• JHHOFXBPLJDHOR-ZJUUUORDSA-N (2s,4s)-4-phenylpyrrolidin-1-ium-2-carboxylate Chemical compound C1N[C@H](C(=O)O)C[C@H]1C1=CC=CC=C1 JHHOFXBPLJDHOR-ZJUUUORDSA-N 0.000 description 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
• XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
• IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
• KUHVCGKIRQEOHA-SAPNQHFASA-N 1,1-dimethyl-3-[(e)-[phenyl(pyridin-2-yl)methylidene]amino]thiourea Chemical compound C=1C=CC=NC=1C(=N/NC(=S)N(C)C)/C1=CC=CC=C1 KUHVCGKIRQEOHA-SAPNQHFASA-N 0.000 description 1
• QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
• WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
• ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
• MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
• CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
• NVFRHTFJDGAFQS-UHFFFAOYSA-N 1-(3,4,5-trihydroxyphenyl)nonan-1-one Chemical compound CCCCCCCCC(=O)C1=CC(O)=C(O)C(O)=C1 NVFRHTFJDGAFQS-UHFFFAOYSA-N 0.000 description 1
• LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
• SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
• VEXRMMJOMMTPKJ-ZVSIBQGLSA-N 1-methyl-3-[(e)-[(1e)-1-(methylcarbamothioylhydrazinylidene)propan-2-ylidene]amino]thiourea Chemical compound CNC(=S)N\N=C\C(\C)=N\NC(=S)NC VEXRMMJOMMTPKJ-ZVSIBQGLSA-N 0.000 description 1
• UTPYTEWRMXITIN-YDWXAUTNSA-N 1-methyl-3-[(e)-[(3e)-3-(methylcarbamothioylhydrazinylidene)butan-2-ylidene]amino]thiourea Chemical compound CNC(=S)N\N=C(/C)\C(\C)=N\NC(=S)NC UTPYTEWRMXITIN-YDWXAUTNSA-N 0.000 description 1
• RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
• 125000004338 2,2,3-trimethylbutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
• LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
• 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 1
• ABEIJMWLNYUWMD-KRWDZBQOSA-N 2-[(5s)-4,7-bis(carboxymethyl)-5-[(4-isothiocyanatophenyl)methyl]-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(=O)O)CCN(CC(O)=O)C[C@@H]1CC1=CC=C(N=C=S)C=C1 ABEIJMWLNYUWMD-KRWDZBQOSA-N 0.000 description 1
• FSOBASOXWBKMSC-QFIPXVFZSA-N 2-[(8s)-3,9-bis(carboxymethyl)-8-[(4-isothiocyanatophenyl)methyl]-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C([C@@H]1N(CC(O)=O)CC=2C=CC=C(N=2)CN(CC(O)=O)CCN(C1)CC(=O)O)C1=CC=C(N=C=S)C=C1 FSOBASOXWBKMSC-QFIPXVFZSA-N 0.000 description 1
• VRELIIISCCUCHF-IBGZPJMESA-N 2-[(9s)-7,10-bis(carboxymethyl)-9-[(4-isothiocyanatophenyl)methyl]-1-oxa-4,7,10-triazacyclododec-4-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCOCCN(CC(O)=O)[C@H]1CC1=CC=C(N=C=S)C=C1 VRELIIISCCUCHF-IBGZPJMESA-N 0.000 description 1
• FHQWIXXRHHMBQL-UHFFFAOYSA-N 2-[1,3,10-tris(carboxymethyl)-1,3,6,10-tetrazacyclododec-6-yl]acetic acid Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CN(CC(O)=O)CC1 FHQWIXXRHHMBQL-UHFFFAOYSA-N 0.000 description 1
• RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 1
• SJBOEHIKNDEHHO-UHFFFAOYSA-N 2-[2-aminoethyl(carboxymethyl)amino]acetic acid Chemical compound NCCN(CC(O)=O)CC(O)=O SJBOEHIKNDEHHO-UHFFFAOYSA-N 0.000 description 1
• XSVWFLQICKPQAA-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1CC(=O)ON1C(=O)CCC1=O XSVWFLQICKPQAA-UHFFFAOYSA-N 0.000 description 1
• DFPHZEYJGWLQJE-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(O)=O)CCN(CC(N)=O)CC1 DFPHZEYJGWLQJE-UHFFFAOYSA-N 0.000 description 1
• LZBLLVHUXJXXNS-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetamide Chemical compound C1N(CC(N)=O)CCN(CC(=O)N)CCN(CC(N)=O)CCN(CC(N)=O)C1CC1=CC=C(N=C=S)C=C1 LZBLLVHUXJXXNS-UHFFFAOYSA-N 0.000 description 1
• ALRKEASEQOCKTJ-UHFFFAOYSA-N 2-[4,7-bis(2-amino-2-oxoethyl)-1,4,7-triazonan-1-yl]acetamide Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)CC1 ALRKEASEQOCKTJ-UHFFFAOYSA-N 0.000 description 1
• AUTDIWAXETZSGJ-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-10-[2-[2-(2,5-dioxopyrrol-1-yl)ethylamino]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1CC(=O)NCCN1C(=O)C=CC1=O AUTDIWAXETZSGJ-UHFFFAOYSA-N 0.000 description 1
• ZILCESMEIDXGNS-UHFFFAOYSA-N 2-[[2-[[2-(3-sulfanylpropanoylamino)acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CCS ZILCESMEIDXGNS-UHFFFAOYSA-N 0.000 description 1
• VASZYFIKPKYGNC-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid;hydrate Chemical compound O.OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O VASZYFIKPKYGNC-UHFFFAOYSA-N 0.000 description 1
• WYMDDFRYORANCC-UHFFFAOYSA-N 2-[[3-[bis(carboxymethyl)amino]-2-hydroxypropyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)CN(CC(O)=O)CC(O)=O WYMDDFRYORANCC-UHFFFAOYSA-N 0.000 description 1
• 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
• 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• WRJZKSHNBALIGH-UHFFFAOYSA-N 2-piperazin-1-ium-1-ylacetate Chemical compound OC(=O)CN1CCNCC1 WRJZKSHNBALIGH-UHFFFAOYSA-N 0.000 description 1
• YFNOTMRKVGZZNF-UHFFFAOYSA-N 2-piperidin-1-ium-4-ylacetate Chemical compound OC(=O)CC1CCNCC1 YFNOTMRKVGZZNF-UHFFFAOYSA-N 0.000 description 1
• ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
• AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
• ZDBWYUOUYNQZBM-UHFFFAOYSA-N 3-(aminomethyl)aniline Chemical compound NCC1=CC=CC(N)=C1 ZDBWYUOUYNQZBM-UHFFFAOYSA-N 0.000 description 1
• GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical compound NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 description 1
• XOBIGRNRXCAMJQ-UHFFFAOYSA-N 3-(dipyridin-2-ylmethylideneamino)-1,1-dimethylthiourea Chemical compound C=1C=CC=NC=1C(=NNC(=S)N(C)C)C1=CC=CC=N1 XOBIGRNRXCAMJQ-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 1
• DMEDOWYXHVUPMO-UHFFFAOYSA-N 4-(carboxymethyl)benzoic acid Chemical compound OC(=O)CC1=CC=C(C(O)=O)C=C1 DMEDOWYXHVUPMO-UHFFFAOYSA-N 0.000 description 1
• HSBKFSPNDWWPSL-CAHLUQPWSA-N 4-amino-5-fluoro-1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1C=C[C@@H](CO)O1 HSBKFSPNDWWPSL-CAHLUQPWSA-N 0.000 description 1
• IIKWGTMGEYTNCQ-UHFFFAOYSA-N 5-(2-aminoethylamino)-5-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]pentanoic acid Chemical compound NCCNC(CCC(C(=O)O)N1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)=O IIKWGTMGEYTNCQ-UHFFFAOYSA-N 0.000 description 1
• CMDFUIYQUYRIHP-UHFFFAOYSA-N 5-[(8-amino-3,6,10,13,16,19-hexazabicyclo[6.6.6]icosan-1-yl)amino]-5-oxopentanoic acid Chemical compound C1NCCNCC2(NC(=O)CCCC(O)=O)CNCCNCC1(N)CNCCNC2 CMDFUIYQUYRIHP-UHFFFAOYSA-N 0.000 description 1
• HBBSDZXXUIHKJE-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=CC=C(C(O)=O)C=N1 HBBSDZXXUIHKJE-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• OOLRAQKFMNOZBV-UHFFFAOYSA-N 8-n-[(4-aminophenyl)methyl]-3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane-1,8-diamine Chemical compound C1=CC(N)=CC=C1CNC1(CNCCNC2)CNCCNCC2(N)CNCCNC1 OOLRAQKFMNOZBV-UHFFFAOYSA-N 0.000 description 1
• 208000003693 Abdominal Fibromatosis Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000016585 Acute panmyelosis with myelofibrosis Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 208000001783 Adamantinoma Diseases 0.000 description 1
• 201000007490 Adenocarcinoma in Situ Diseases 0.000 description 1
• 208000000583 Adenolymphoma Diseases 0.000 description 1
• 208000005748 Aggressive Fibromatosis Diseases 0.000 description 1
• 208000035805 Aleukaemic leukaemia Diseases 0.000 description 1
• 229910052695 Americium Inorganic materials 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 206010051810 Angiomyolipoma Diseases 0.000 description 1
• 201000000153 Angiomyoma Diseases 0.000 description 1
• 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
• CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
• 206010064755 Atypical fibroxanthoma Diseases 0.000 description 1
• 208000037398 BCR-ABL1 negative atypical chronic myeloid leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 201000009586 Basophil Adenoma Diseases 0.000 description 1
• 206010004272 Benign hydatidiform mole Diseases 0.000 description 1
• 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
• 208000035821 Benign schwannoma Diseases 0.000 description 1
• 229910052694 Berkelium Inorganic materials 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 201000008474 Borst-Jadassohn intraepidermal carcinoma Diseases 0.000 description 1
• 208000013165 Bowen disease Diseases 0.000 description 1
• 208000019337 Bowen disease of the skin Diseases 0.000 description 1
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• NOHFVHQBEMKKMB-UHFFFAOYSA-N C(=O)(O)C(CCC(=O)NCCN1C(C=CC1=O)=O)N1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O Chemical compound C(=O)(O)C(CCC(=O)NCCN1C(C=CC1=O)=O)N1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O NOHFVHQBEMKKMB-UHFFFAOYSA-N 0.000 description 1
• YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 101150061050 CIN1 gene Proteins 0.000 description 1
• 101150070189 CIN3 gene Proteins 0.000 description 1
• 208000008207 Calcifying Odontogenic Cyst Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229910052686 Californium Inorganic materials 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 208000001843 Carotid Body Tumor Diseases 0.000 description 1
• 208000037211 Carotid body tumour Diseases 0.000 description 1
• 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
• 206010062564 Cementoblastoma Diseases 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 229910052684 Cerium Inorganic materials 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008583 Chloroma Diseases 0.000 description 1
• 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 208000019591 Chondromyxoid fibroma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 1
• GUTLYIVDDKVIGB-AHCXROLUSA-N Cobalt-55 Chemical compound [55Co] GUTLYIVDDKVIGB-AHCXROLUSA-N 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
• 206010065859 Congenital fibrosarcoma Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 229910052685 Curium Inorganic materials 0.000 description 1
• 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
• 201000005171 Cystadenoma Diseases 0.000 description 1
• 239000011665 D-biotin Substances 0.000 description 1
• 235000000638 D-biotin Nutrition 0.000 description 1
• 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
• 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
• 208000001154 Dermoid Cyst Diseases 0.000 description 1
• 206010059352 Desmoid tumour Diseases 0.000 description 1
• 208000007148 Desmoplastic Fibroma Diseases 0.000 description 1
• 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 1
• 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 1
• 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 1
• 101710087012 Dipeptidyl-peptidase 7 Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000007033 Dysgerminoma Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 229910052690 Einsteinium Inorganic materials 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 208000027666 Endometrial Stromal Tumors Diseases 0.000 description 1
• 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
• 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
• 208000002519 Epithelioid Leiomyoma Diseases 0.000 description 1
• 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 208000003021 Erythroplasia Diseases 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 102000018389 Exopeptidases Human genes 0.000 description 1
• 108010091443 Exopeptidases Proteins 0.000 description 1
• 101150027576 FAP gene Proteins 0.000 description 1
• 206010016228 Fasciitis Diseases 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 208000007842 Fibroepithelial Neoplasms Diseases 0.000 description 1
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
• 201000004066 Ganglioglioma Diseases 0.000 description 1
• 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
• 206010051709 Gastrinoma malignant Diseases 0.000 description 1
• 201000008540 Gemistocytic astrocytoma Diseases 0.000 description 1
• 208000000527 Germinoma Diseases 0.000 description 1
• 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
• 101710088083 Glomulin Proteins 0.000 description 1
• 208000009789 Glomus Jugulare Tumor Diseases 0.000 description 1
• 208000037179 Glomus jugulare tumour Diseases 0.000 description 1
• 206010018381 Glomus tumour Diseases 0.000 description 1
• FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
• 206010060980 Granular cell tumour Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 208000035773 Gynandroblastoma Diseases 0.000 description 1
• IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
• 206010068785 Histiocytic medullary reticulosis Diseases 0.000 description 1
• 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 1
• 208000017628 Hodgkin disease lymphocyte predominance type stage unspecified Diseases 0.000 description 1
• 208000017609 Hodgkin disease mixed cellularity stage unspecified Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000025786 Hodgkin paragranuloma Diseases 0.000 description 1
• 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 1
• 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 description 1
• 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 208000005125 Invasive Hydatidiform Mole Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
• QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• 229930195722 L-methionine Natural products 0.000 description 1
• HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
• 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
• 229910052766 Lawrencium Inorganic materials 0.000 description 1
• 208000001791 Leiomyomatosis Diseases 0.000 description 1
• 206010024218 Lentigo maligna Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000000265 Lobular Carcinoma Diseases 0.000 description 1
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
• 201000002171 Luteoma Diseases 0.000 description 1
• 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 1
• 208000004138 Lymphangiomyoma Diseases 0.000 description 1
• 208000010423 Lymphatic Vessel Tumors Diseases 0.000 description 1
• NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
• 101710151321 Melanostatin Proteins 0.000 description 1
• 208000007343 Melanotic Neuroectodermal Tumor Diseases 0.000 description 1
• 229910052764 Mendelevium Inorganic materials 0.000 description 1
• 206010027193 Meningioma malignant Diseases 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 206010070665 Mesoblastic nephroma Diseases 0.000 description 1
• 208000009739 Mesodermal Mixed Tumor Diseases 0.000 description 1
• 206010027407 Mesothelioma malignant Diseases 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 208000002406 Mucoepidermoid Tumor Diseases 0.000 description 1
• 208000010357 Mullerian Mixed Tumor Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 208000007182 Myelolipoma Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• 208000009287 Myoepithelioma Diseases 0.000 description 1
• 201000004458 Myoma Diseases 0.000 description 1
• 208000005927 Myosarcoma Diseases 0.000 description 1
• 206010066948 Myxofibrosarcoma Diseases 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• 108010079364 N-glycylalanine Proteins 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 229910052779 Neodymium Inorganic materials 0.000 description 1
• 208000031675 Neoplasms, Adnexal and Skin Appendage Diseases 0.000 description 1
• 208000002928 Neoplasms, Ductal, Lobular, and Medullary Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 229910052781 Neptunium Inorganic materials 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000008846 Neurocytoma Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 102400000064 Neuropeptide Y Human genes 0.000 description 1
• 208000006964 Nevi and Melanomas Diseases 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
• 208000026616 Ollier disease Diseases 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 208000001715 Osteoblastoma Diseases 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 208000006024 Osteochondromatosis Diseases 0.000 description 1
• 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
• 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
• 201000004441 Pacinian tumor Diseases 0.000 description 1
• 208000027067 Paget disease of bone Diseases 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 206010033733 Papule Diseases 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 206010033963 Parathyroid tumour Diseases 0.000 description 1
• 108010088847 Peptide YY Proteins 0.000 description 1
• 102100029909 Peptide YY Human genes 0.000 description 1
• 102000004503 Perforin Human genes 0.000 description 1
• 108010056995 Perforin Proteins 0.000 description 1
• 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 201000010395 Pleomorphic liposarcoma Diseases 0.000 description 1
• 229910052778 Plutonium Inorganic materials 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229910052777 Praseodymium Inorganic materials 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
• 229910052773 Promethium Inorganic materials 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
• 208000001671 Pulmonary Adenomatosis Diseases 0.000 description 1
• 239000005700 Putrescine Substances 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 206010073139 Round cell liposarcoma Diseases 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• 229910006069 SO3H Inorganic materials 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 201000001542 Schneiderian carcinoma Diseases 0.000 description 1
• 208000006938 Schwannomatosis Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
• 201000011683 Small Cell Sarcoma Diseases 0.000 description 1
• 206010054184 Small intestine carcinoma Diseases 0.000 description 1
• 206010073118 Spermatocytic seminoma Diseases 0.000 description 1
• 208000008093 Squamous Odontogenic Tumor Diseases 0.000 description 1
• 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
• 208000001662 Subependymal Glioma Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
• UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
• 239000005864 Sulphur Substances 0.000 description 1
• 208000025194 Sweat Gland Neoplasms Diseases 0.000 description 1
• UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
• 206010048460 Teratoma benign Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 201000000331 Testicular germ cell cancer Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
• QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
• GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 206010061031 Thymoma malignant Diseases 0.000 description 1
• 208000033781 Thyroid carcinoma Diseases 0.000 description 1
• LYJKREGDQDJIDC-UHFFFAOYSA-N Tirandamycin B Natural products O1C(C2(OC2C2=O)CO)(C)OC2C(C)C1C(C)C=C(C)C=CC(O)=C1C(=O)CNC1=O LYJKREGDQDJIDC-UHFFFAOYSA-N 0.000 description 1
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
• 239000007997 Tricine buffer Substances 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 208000006288 Vascular Tissue Neoplasms Diseases 0.000 description 1
• 208000029616 Verrucous hemangioma Diseases 0.000 description 1
• 208000021146 Warthin tumor Diseases 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• OXYYOEIGQRXGPI-WSZWBAFRSA-N [(2s)-1-[(2r)-2-boronopyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]azanium;methanesulfonate Chemical compound CS(O)(=O)=O.CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O OXYYOEIGQRXGPI-WSZWBAFRSA-N 0.000 description 1
• IJGRMHOSHXDMSA-BJUDXGSMSA-N [13N]#N Chemical compound [13N]#N IJGRMHOSHXDMSA-BJUDXGSMSA-N 0.000 description 1
• 210000005022 abdominal esophagus Anatomy 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• CYJYKTMBMMYRHR-UHFFFAOYSA-N acetic acid;1,4,7-triazonane Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.C1CNCCNCCN1 CYJYKTMBMMYRHR-UHFFFAOYSA-N 0.000 description 1
• 208000005310 acidophil adenoma Diseases 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
• 150000001263 acyl chlorides Chemical class 0.000 description 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
• 208000026562 adenomatoid odontogenic tumor Diseases 0.000 description 1
• 208000002718 adenomatoid tumor Diseases 0.000 description 1
• 208000002938 adenomyoma Diseases 0.000 description 1
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000026565 adrenal gland myelolipoma Diseases 0.000 description 1
• 201000002515 adrenal rest tumor Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
• 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
• 201000010614 alveoli adenoma Diseases 0.000 description 1
• LXQXZNRPTYVCNG-UHFFFAOYSA-N americium atom Chemical compound [Am] LXQXZNRPTYVCNG-UHFFFAOYSA-N 0.000 description 1
• 229960004050 aminobenzoic acid Drugs 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
• 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 201000009431 angiokeratoma Diseases 0.000 description 1
• 208000020716 angioleiomyoma Diseases 0.000 description 1
• 201000002196 angiomatous meningioma Diseases 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 239000000611 antibody drug conjugate Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
• 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
• 201000005130 apocrine adenoma Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 208000016927 arteriovenous hemangioma/malformation Diseases 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 125000000732 arylene group Chemical group 0.000 description 1
• 210000001815 ascending colon Anatomy 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 108010038633 aspartylglutamate Proteins 0.000 description 1
• RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
• 201000005476 astroblastoma Diseases 0.000 description 1
• 201000004892 atypical chronic myeloid leukemia Diseases 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 201000000036 balloon cell malignant melanoma Diseases 0.000 description 1
• 238000002869 basic local alignment search tool Methods 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 208000012999 benign epithelial neoplasm Diseases 0.000 description 1
• 208000013981 benign spiradenoma Diseases 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
• 239000012964 benzotriazole Substances 0.000 description 1
• PWVKJRSRVJTHTR-UHFFFAOYSA-N berkelium atom Chemical compound [Bk] PWVKJRSRVJTHTR-UHFFFAOYSA-N 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• 201000002097 bile duct cystadenocarcinoma Diseases 0.000 description 1
• 201000002024 bile duct cystadenoma Diseases 0.000 description 1
• 208000028840 bile duct mucinous cystic neoplasm with an associated invasive carcinoma Diseases 0.000 description 1
• 201000001396 biphasic synovial sarcoma Diseases 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 201000002846 bizarre leiomyoma Diseases 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 201000011177 bladder transitional cell papilloma Diseases 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000003995 blood forming stem cell Anatomy 0.000 description 1
• 208000016738 bone Paget disease Diseases 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• 125000005620 boronic acid group Chemical group 0.000 description 1
• 201000005389 breast carcinoma in situ Diseases 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 201000011054 breast malignant phyllodes tumor Diseases 0.000 description 1
• 201000005175 breast pericanalicular fibroadenoma Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 229910052793 cadmium Inorganic materials 0.000 description 1
• BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
• 208000010437 calcifying epithelial odontogenic tumor Diseases 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• HGLDOAKPQXAFKI-UHFFFAOYSA-N californium atom Chemical compound [Cf] HGLDOAKPQXAFKI-UHFFFAOYSA-N 0.000 description 1
• 102000006783 calponin Human genes 0.000 description 1
• 108010086826 calponin Proteins 0.000 description 1
• 208000001969 capillary hemangioma Diseases 0.000 description 1
• 201000007163 capillary lymphangioma Diseases 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 208000025106 carcinoma of duodenum Diseases 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000008355 cartilage degradation Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 201000003340 cellular leiomyoma Diseases 0.000 description 1
• 201000010882 cellular myxoid liposarcoma Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
• 201000004226 ceruminoma Diseases 0.000 description 1
• 201000002891 ceruminous adenocarcinoma Diseases 0.000 description 1
• 208000024188 ceruminous carcinoma Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 210000005023 cervical esophagus Anatomy 0.000 description 1
• 239000012986 chain transfer agent Substances 0.000 description 1
• 150000004697 chelate complex Chemical class 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 201000003688 chief cell adenoma Diseases 0.000 description 1
• 201000008863 chondroblastic osteosarcoma Diseases 0.000 description 1
• 208000020719 chondrogenic neoplasm Diseases 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• VYZAMTAEIAYCRO-AHCXROLUSA-N chromium-48 Chemical compound [48Cr] VYZAMTAEIAYCRO-AHCXROLUSA-N 0.000 description 1
• 208000009339 chromophobe adenoma Diseases 0.000 description 1
• 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
• 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
• 201000011554 chronic erythremia Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
• PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
• 201000000898 clear cell adenofibroma Diseases 0.000 description 1
• 201000002141 clear cell adenoma Diseases 0.000 description 1
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
• 201000000292 clear cell sarcoma Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 201000007571 cloacogenic carcinoma Diseases 0.000 description 1
• 230000036569 collagen breakdown Effects 0.000 description 1
• 201000007796 colloid adenoma Diseases 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 208000026814 combined carcinoid and adenocarcinoma Diseases 0.000 description 1
• 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000013170 computed tomography imaging Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• RYGMFSIKBFXOCR-AHCXROLUSA-N copper-60 Chemical compound [60Cu] RYGMFSIKBFXOCR-AHCXROLUSA-N 0.000 description 1
• 201000011063 cribriform carcinoma Diseases 0.000 description 1
• NIWWFAAXEMMFMS-UHFFFAOYSA-N curium atom Chemical compound [Cm] NIWWFAAXEMMFMS-UHFFFAOYSA-N 0.000 description 1
• 150000001923 cyclic compounds Chemical class 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 208000007321 cystadenofibroma Diseases 0.000 description 1
• 208000014014 cystic hygroma Diseases 0.000 description 1
• 208000003688 cystic lymphangioma Diseases 0.000 description 1
• 208000012207 cystic, mucinous, and serous neoplasm Diseases 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 229960000958 deferoxamine Drugs 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 210000001731 descending colon Anatomy 0.000 description 1
• 229940099217 desferal Drugs 0.000 description 1
• 201000006827 desmoid tumor Diseases 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 208000017055 digestive system neuroendocrine neoplasm Diseases 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 150000004662 dithiols Chemical class 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
• 201000001013 eccrine acrospiroma Diseases 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• CKBRQZNRCSJHFT-UHFFFAOYSA-N einsteinium atom Chemical compound [Es] CKBRQZNRCSJHFT-UHFFFAOYSA-N 0.000 description 1
• 208000029509 elastofibroma dorsi Diseases 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 201000000330 endometrial stromal sarcoma Diseases 0.000 description 1
• 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
• 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 208000010932 epithelial neoplasm Diseases 0.000 description 1
• 208000011524 epithelioid cell nevus Diseases 0.000 description 1
• 201000001401 epithelioid cell synovial sarcoma Diseases 0.000 description 1
• 201000002658 epithelioid leiomyosarcoma Diseases 0.000 description 1
• UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
• 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 229940052303 ethers for general anesthesia Drugs 0.000 description 1
• 235000019439 ethyl acetate Nutrition 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• MIORUQGGZCBUGO-UHFFFAOYSA-N fermium Chemical compound [Fm] MIORUQGGZCBUGO-UHFFFAOYSA-N 0.000 description 1
• 201000010009 fetal adenoma Diseases 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
• 230000003328 fibroblastic effect Effects 0.000 description 1
• 208000020336 fibromyxoid tumor Diseases 0.000 description 1
• 230000000893 fibroproliferative effect Effects 0.000 description 1
• 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
• 201000003671 fibrosarcomatous osteosarcoma Diseases 0.000 description 1
• 201000006986 fibrous meningioma Diseases 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 230000004992 fission Effects 0.000 description 1
• YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
• 201000004260 follicular adenoma Diseases 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 208000030878 follicular thyroid adenoma Diseases 0.000 description 1
• 229910052730 francium Inorganic materials 0.000 description 1
• KLMCZVJOEAUDNE-UHFFFAOYSA-N francium atom Chemical compound [Fr] KLMCZVJOEAUDNE-UHFFFAOYSA-N 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• KXTYBXCEQOANSX-WYKQKOHHSA-N fusicoccin Chemical compound O([C@H]1[C@H](O)[C@H](C)[C@@H]\2CC[C@@H](C/2=C/[C@@]2(C)[C@@H](O)CC(=C21)[C@H](C)COC(C)=O)COC)[C@H]1O[C@H](COC(C)(C)C=C)[C@@H](O)[C@H](OC(C)=O)[C@H]1O KXTYBXCEQOANSX-WYKQKOHHSA-N 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 230000005251 gamma ray Effects 0.000 description 1
• 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• SSBRJDBGIVUNDK-QOGDCIHTSA-N gastrin-14 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSBRJDBGIVUNDK-QOGDCIHTSA-N 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 201000003115 germ cell cancer Diseases 0.000 description 1
• 201000005626 glomangioma Diseases 0.000 description 1
• 201000002264 glomangiosarcoma Diseases 0.000 description 1
• VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 208000003064 gonadoblastoma Diseases 0.000 description 1
• 201000007574 granular cell carcinoma Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229910052735 hafnium Inorganic materials 0.000 description 1
• VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 208000009117 halo nevus Diseases 0.000 description 1
• 210000001983 hard palate Anatomy 0.000 description 1
• 201000000615 hard palate cancer Diseases 0.000 description 1
• 229910021473 hassium Inorganic materials 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical class [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 210000004024 hepatic stellate cell Anatomy 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 208000027833 hibernoma Diseases 0.000 description 1
• 201000005133 hidradenoma Diseases 0.000 description 1
• 208000006634 hidrocystoma Diseases 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
• PQZHJQDTAMHWKF-UHFFFAOYSA-N hydroxy hypobromite Chemical compound OOBr PQZHJQDTAMHWKF-UHFFFAOYSA-N 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 150000002471 indium Chemical class 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 201000008600 infiltrating lipoma Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 201000000723 infiltrative basal cell carcinoma Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 201000006859 intermediate malignant teratoma Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 201000004472 intracystic papillary adenoma Diseases 0.000 description 1
• 208000007098 intradermal nevus Diseases 0.000 description 1
• 201000003159 intraductal papilloma Diseases 0.000 description 1
• 208000029206 intraductal papillomatosis Diseases 0.000 description 1
• 201000009370 intramuscular hemangioma Diseases 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 208000024312 invasive carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 201000010151 inverted papilloma Diseases 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 229910052741 iridium Inorganic materials 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• XEEYBQQBJWHFJM-AHCXROLUSA-N iron-52 Chemical compound [52Fe] XEEYBQQBJWHFJM-AHCXROLUSA-N 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
• 201000005263 juxtacortical chondroma Diseases 0.000 description 1
• 201000009493 juxtacortical chondrosarcoma Diseases 0.000 description 1
• 201000000462 keratinizing squamous cell carcinoma Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 210000001865 kupffer cell Anatomy 0.000 description 1
• 229910052746 lanthanum Inorganic materials 0.000 description 1
• FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• CNQCVBJFEGMYDW-UHFFFAOYSA-N lawrencium atom Chemical compound [Lr] CNQCVBJFEGMYDW-UHFFFAOYSA-N 0.000 description 1
• 229910052745 lead Inorganic materials 0.000 description 1
• 208000029805 leather-bottle stomach Diseases 0.000 description 1
• 208000027884 letterer-Siwe disease Diseases 0.000 description 1
• 210000002332 leydig cell Anatomy 0.000 description 1
• 206010024520 linitis plastica Diseases 0.000 description 1
• 125000003473 lipid group Chemical group 0.000 description 1
• 230000013190 lipid storage Effects 0.000 description 1
• 201000002156 lipoadenoma Diseases 0.000 description 1
• 208000010033 lipoblastoma Diseases 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 201000011059 lobular neoplasia Diseases 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
• 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
• 208000024169 luteoma of pregnancy Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
• 150000002678 macrocyclic compounds Chemical class 0.000 description 1
• 208000026662 macrocystic lymphatic malformation Diseases 0.000 description 1
• 201000011150 malignant giant cell tumor of soft parts Diseases 0.000 description 1
• 208000018013 malignant glomus tumor Diseases 0.000 description 1
• 201000004102 malignant granular cell myoblastoma Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
• 208000026267 malignant phyllodes tumor Diseases 0.000 description 1
• 208000000516 mast-cell leukemia Diseases 0.000 description 1
• 201000008749 mast-cell sarcoma Diseases 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 201000005776 medullomyoblastoma Diseases 0.000 description 1
• 208000016056 medullomyoblastoma with myogenic differentiation Diseases 0.000 description 1
• 201000002699 melanoma in congenital melanocytic nevus Diseases 0.000 description 1
• 230000000684 melanotic effect Effects 0.000 description 1
• MQVSLOYRCXQRPM-UHFFFAOYSA-N mendelevium atom Chemical compound [Md] MQVSLOYRCXQRPM-UHFFFAOYSA-N 0.000 description 1
• 201000007007 meningothelial meningioma Diseases 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 108010076432 minigastrin Proteins 0.000 description 1
• 201000002026 mixed cell adenoma Diseases 0.000 description 1
• 201000010225 mixed cell type cancer Diseases 0.000 description 1
• 208000037524 mixed cellularity Hodgkin lymphoma Diseases 0.000 description 1
• 201000007573 mixed eosinophil-basophil adenoma Diseases 0.000 description 1
• 201000004058 mixed glioma Diseases 0.000 description 1
• 208000029638 mixed neoplasm Diseases 0.000 description 1
• 201000002139 mixed type rhabdomyosarcoma Diseases 0.000 description 1
• 206010073136 mixed-type liposarcoma Diseases 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000011733 molybdenum Substances 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 201000004591 mucinous adenofibroma Diseases 0.000 description 1
• 201000009368 muscle benign neoplasm Diseases 0.000 description 1
• 201000002077 muscle cancer Diseases 0.000 description 1
• 201000005987 myeloid sarcoma Diseases 0.000 description 1
• 230000002071 myeloproliferative effect Effects 0.000 description 1
• 208000026226 myoepithelial tumor Diseases 0.000 description 1
• 208000017708 myomatous neoplasm Diseases 0.000 description 1
• 201000004057 myxopapillary ependymoma Diseases 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
• YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
• MTHMMXFBHKGAAI-UHFFFAOYSA-N n-[2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl]quinoline-4-carboxamide Chemical compound C=1C=NC2=CC=CC=C2C=1C(=O)NCC(=O)N1CCCC1C#N MTHMMXFBHKGAAI-UHFFFAOYSA-N 0.000 description 1
• LEHVOVFBWKETSG-NRFANRHFSA-N n-amino-n'-[(4s)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]-5-(4-methylpiperidin-1-yl)-5-oxopentyl]methanimidamide Chemical compound C1CC(C)CCN1C(=O)[C@H](CCCN=CNN)NS(=O)(=O)C1=CC=CC2=C(N(C)C)C=CC=C12 LEHVOVFBWKETSG-NRFANRHFSA-N 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
• OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
• QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
• 208000018221 neoplasm of aortic body Diseases 0.000 description 1
• LFNLGNPSGWYGGD-UHFFFAOYSA-N neptunium atom Chemical compound [Np] LFNLGNPSGWYGGD-UHFFFAOYSA-N 0.000 description 1
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 208000029986 neuroepithelioma Diseases 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• PXHVJJICTQNCMI-OIOBTWANSA-N nickel-56 Chemical compound [56Ni] PXHVJJICTQNCMI-OIOBTWANSA-N 0.000 description 1
• MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
• ORQBXQOJMQIAOY-UHFFFAOYSA-N nobelium Chemical compound [No] ORQBXQOJMQIAOY-UHFFFAOYSA-N 0.000 description 1
• 208000025275 nodular sclerosis classical Hodgkin lymphoma Diseases 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 201000009804 nonencapsulated sclerosing carcinoma Diseases 0.000 description 1
• 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 229940127059 octreoscan Drugs 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 208000013806 oncocytic adenoma Diseases 0.000 description 1
• 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 210000000277 pancreatic duct Anatomy 0.000 description 1
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
• 201000010148 papillary adenoma Diseases 0.000 description 1
• 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
• 201000000393 papillary ependymoma Diseases 0.000 description 1
• 208000029178 papillary meningioma Diseases 0.000 description 1
• 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
• 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
• 201000010941 papillary squamous carcinoma Diseases 0.000 description 1
• 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
• 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
• 208000029211 papillomatosis Diseases 0.000 description 1
• 208000029532 parasympathetic paraganglioma Diseases 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 210000003668 pericyte Anatomy 0.000 description 1
• 208000024975 periosteal chondroma Diseases 0.000 description 1
• 201000009530 periosteal chondrosarcoma Diseases 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 208000001095 pilomatrixoma Diseases 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 206010035059 pineocytoma Diseases 0.000 description 1
• 208000020788 pituitary gland acidophil adenoma Diseases 0.000 description 1
• 208000029354 pituitary gland mixed eosinophil-basophil adenoma Diseases 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 208000004333 pleomorphic adenoma Diseases 0.000 description 1
• 201000010968 pleomorphic carcinoma Diseases 0.000 description 1
• 201000009463 pleomorphic rhabdomyosarcoma Diseases 0.000 description 1
• 208000004748 plexiform neurofibroma Diseases 0.000 description 1
• OYEHPCDNVJXUIW-UHFFFAOYSA-N plutonium atom Chemical compound [Pu] OYEHPCDNVJXUIW-UHFFFAOYSA-N 0.000 description 1
• 229910052699 polonium Inorganic materials 0.000 description 1
• HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 1
• 208000024246 polyembryoma Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 210000001316 polygonal cell Anatomy 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000003476 primary myelofibrosis Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
• 201000006988 psammomatous meningioma Diseases 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 210000004203 pyloric antrum Anatomy 0.000 description 1
• 210000001187 pylorus Anatomy 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 239000000700 radioactive tracer Substances 0.000 description 1
• 238000011127 radiochemotherapy Methods 0.000 description 1
• 229940051022 radioimmunoconjugate Drugs 0.000 description 1
• 229910052705 radium Inorganic materials 0.000 description 1
• HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
• 229910052704 radon Inorganic materials 0.000 description 1
• SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 230000003307 reticuloendothelial effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 208000028666 rhabdomyosarcoma with mixed embryonal and alveolar features Diseases 0.000 description 1
• WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
• MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229910021481 rutherfordium Inorganic materials 0.000 description 1
• YGPLJIIQQIDVFJ-UHFFFAOYSA-N rutherfordium atom Chemical compound [Rf] YGPLJIIQQIDVFJ-UHFFFAOYSA-N 0.000 description 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
• KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
• 201000003774 sarcomatosis Diseases 0.000 description 1
• 201000003769 sarcomatosis of the meninges Diseases 0.000 description 1
• SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 208000004259 scirrhous adenocarcinoma Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 229910021477 seaborgium Inorganic materials 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 201000005218 sebaceous adenoma Diseases 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 239000011669 selenium Substances 0.000 description 1
• UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
• 208000011844 serous adenofibroma Diseases 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 210000001599 sigmoid colon Anatomy 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 239000010944 silver (metal) Substances 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 210000001584 soft palate Anatomy 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 201000009686 spermatocytoma Diseases 0.000 description 1
• 201000002245 spindle cell lipoma Diseases 0.000 description 1
• 208000008542 spindle cell nevus Diseases 0.000 description 1
• 201000000270 spindle cell sarcoma Diseases 0.000 description 1
• 201000001019 spiradenoma Diseases 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 201000010159 squamous cell papilloma Diseases 0.000 description 1
• 208000017015 squamous papilloma Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 201000009444 subacute leukemia Diseases 0.000 description 1
• 201000005955 subacute monocytic leukemia Diseases 0.000 description 1
• 201000004867 subacute myeloid leukemia Diseases 0.000 description 1
• 201000004274 subareolar duct papillomatosis Diseases 0.000 description 1
• 201000004059 subependymal giant cell astrocytoma Diseases 0.000 description 1
• 208000030819 subependymoma Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000003459 sulfonic acid esters Chemical class 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 210000000106 sweat gland Anatomy 0.000 description 1
• 208000003080 sweat gland adenoma Diseases 0.000 description 1
• 208000027371 sweat gland benign neoplasm Diseases 0.000 description 1
• 208000012190 sympathetic paraganglioma Diseases 0.000 description 1
• 210000005222 synovial tissue Anatomy 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 201000008753 synovium neoplasm Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 201000000999 syringocystadenoma papilliferum Diseases 0.000 description 1
• 208000004022 syringoma Diseases 0.000 description 1
• 229910052715 tantalum Inorganic materials 0.000 description 1
• GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
• 201000011080 telangiectatic osteogenic sarcoma Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• 208000022375 teratoma with malignant transformation Diseases 0.000 description 1
• GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
• TVUPYCMMXREXSS-UHFFFAOYSA-N tert-butyl 2-[4-[2-(2-aminoethylamino)-2-oxoethyl]-7,10-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetate Chemical compound CC(C)(C)OC(=O)CN1CCN(CC(=O)NCCN)CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1 TVUPYCMMXREXSS-UHFFFAOYSA-N 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 150000004685 tetrahydrates Chemical class 0.000 description 1
• UJJLJRQIPMGXEZ-SCSAIBSYSA-N tetrahydrofuran-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCO1 UJJLJRQIPMGXEZ-SCSAIBSYSA-N 0.000 description 1
• 229910052716 thallium Inorganic materials 0.000 description 1
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
• 210000003684 theca cell Anatomy 0.000 description 1
• 125000000101 thioether group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 210000005018 thoracic esophagus Anatomy 0.000 description 1
• ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical class [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 description 1
• 230000002885 thrombogenetic effect Effects 0.000 description 1
• FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
• 208000026308 thyroid gland diffuse sclerosing papillary carcinoma Diseases 0.000 description 1
• 208000029481 thyroid gland fetal adenoma Diseases 0.000 description 1
• 208000021211 thyroid gland macrofollicular adenoma Diseases 0.000 description 1
• 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 229910052718 tin Inorganic materials 0.000 description 1
• URGUBECARCAPRI-UHFFFAOYSA-N tirandamycin A Natural products O1C(C2(OC2C2=O)C)(C)OC2C(C)C1C(C)C=C(C)C=CC(O)=C1C(=O)CNC1=O URGUBECARCAPRI-UHFFFAOYSA-N 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 239000010936 titanium Substances 0.000 description 1
• 229910052719 titanium Inorganic materials 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
• 208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
• GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
• 229960000401 tranexamic acid Drugs 0.000 description 1
• BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
• URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 1
• 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 201000007003 transitional meningioma Diseases 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 208000000654 trichofolliculoma Diseases 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
• 230000001573 trophoblastic effect Effects 0.000 description 1
• 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
• 201000007423 tubular adenocarcinoma Diseases 0.000 description 1
• 208000022271 tubular adenoma Diseases 0.000 description 1
• 208000022158 tubulovillous adenoma Diseases 0.000 description 1
• 208000025443 tumor of adipose tissue Diseases 0.000 description 1
• 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
• 238000007473 univariate analysis Methods 0.000 description 1
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
• 210000003803 urachus Anatomy 0.000 description 1
• JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
• 230000002620 ureteric effect Effects 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 208000012477 urothelial papilloma Diseases 0.000 description 1
• 210000002396 uvula Anatomy 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
• 201000011531 vascular cancer Diseases 0.000 description 1
• 230000009790 vascular invasion Effects 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 201000009371 venous hemangioma Diseases 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• 201000009382 verrucous keratotic hemangioma Diseases 0.000 description 1
• 201000010152 verrucous papilloma Diseases 0.000 description 1
• 201000007553 villous adenocarcinoma Diseases 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 201000001132 water-clear cell adenoma Diseases 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1